Treace Medical to Showcase Bunion Surgery Innovations at J.P. Morgan Healthcare Conference
Treace Medical Concepts, Inc. (TMCI) will participate in the 44th Annual J.P. Morgan Healthcare Conference next month. CEO John T. Treace is scheduled to speak on January 14, 2026, at 7:30 am Pacific Time. The company, based in Ponte Vedra, Florida, specializes in surgical solutions for bunions and midfoot deformities, a condition affecting millions of Americans each year.
Treace announced the presentation on December 30, 2025, confirming that a live webcast and replay would be available on its investor relations website. The company routinely shares key updates there, alongside its main site, www.treace.com.
The firm focuses on advancing bunion treatment through systems like the patented Lapiplasty 3D Bunion Correction, which targets the root cause of deformities. Its product range also includes the Adductoplasty Midfoot Correction System, minimally invasive osteotomy tools (Nanoplasty and Percuplasty), and the SpeedMTP MTP Fusion System. Additionally, Treace is expanding its SpeedPlate rapid compression implant platform and offers digital planning tools such as IntelliGuide for patient-specific pre-op guidance. For investor inquiries, the Gilmartin Group manages relations at [email protected]. Chief Financial Officer Mark L. Hair can be reached directly at [email protected] or by phone at (904) 373-5940.
Treace’s technologies aim to improve outcomes for the 67 million Americans with bunions, including 1.1 million surgical candidates annually. The upcoming conference presentation will likely highlight the company’s progress in surgical innovation and investor communications. Further details will be accessible via the webcast and Treace’s official channels.
